%0 Journal Article
%T Natalizumab versus fingolimod and dimethyl fumarate in multiple sclerosis treatment
%A Brandi L. Vollmer
%A John R. Corboy
%A Kavita V. Nair
%A Stefan Sillau
%A Timothy Vollmer
%J Archive of "Annals of Clinical and Translational Neurology".
%D 2019
%R 10.1002/acn3.700
%X To compare 2©\year effectiveness and discontinuation of natalizumab (NTZ) versus fingolimod (FTY) and dimethyl fumarate (DMF) in the treatment of multiple sclerosis (MS)
%U https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6389745/